Tarsus Pharmaceuticals Inc
NASDAQ:TARS

Watchlist Manager
Tarsus Pharmaceuticals Inc Logo
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Watchlist
Price: 48.24 USD 3.97% Market Closed
Market Cap: 1.8B USD
Have any thoughts about
Tarsus Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one TARS stock under the Base Case scenario is 33.67 USD. Compared to the current market price of 48.24 USD, Tarsus Pharmaceuticals Inc is Overvalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TARS Intrinsic Value
33.67 USD
Overvaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Tarsus Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TARS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TARS?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Tarsus Pharmaceuticals Inc

Provide an overview of the primary business activities
of Tarsus Pharmaceuticals Inc.

What unique competitive advantages
does Tarsus Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Tarsus Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Tarsus Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Tarsus Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Tarsus Pharmaceuticals Inc.

Provide P/S
for Tarsus Pharmaceuticals Inc.

Provide P/E
for Tarsus Pharmaceuticals Inc.

Provide P/OCF
for Tarsus Pharmaceuticals Inc.

Provide P/FCFE
for Tarsus Pharmaceuticals Inc.

Provide P/B
for Tarsus Pharmaceuticals Inc.

Provide EV/S
for Tarsus Pharmaceuticals Inc.

Provide EV/GP
for Tarsus Pharmaceuticals Inc.

Provide EV/EBITDA
for Tarsus Pharmaceuticals Inc.

Provide EV/EBIT
for Tarsus Pharmaceuticals Inc.

Provide EV/OCF
for Tarsus Pharmaceuticals Inc.

Provide EV/FCFF
for Tarsus Pharmaceuticals Inc.

Provide EV/IC
for Tarsus Pharmaceuticals Inc.

Show me price targets
for Tarsus Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Tarsus Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Tarsus Pharmaceuticals Inc?

What are the Net Income projections
for Tarsus Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Tarsus Pharmaceuticals Inc?

What are the EPS projections
for Tarsus Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Tarsus Pharmaceuticals Inc?

What are the EBIT projections
for Tarsus Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Tarsus Pharmaceuticals Inc?

Compare the revenue forecasts
for Tarsus Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Tarsus Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Tarsus Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Tarsus Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Tarsus Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Tarsus Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Tarsus Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Tarsus Pharmaceuticals Inc.

Provide ROE
for Tarsus Pharmaceuticals Inc.

Provide ROA
for Tarsus Pharmaceuticals Inc.

Provide ROIC
for Tarsus Pharmaceuticals Inc.

Provide ROCE
for Tarsus Pharmaceuticals Inc.

Provide Gross Margin
for Tarsus Pharmaceuticals Inc.

Provide Operating Margin
for Tarsus Pharmaceuticals Inc.

Provide Net Margin
for Tarsus Pharmaceuticals Inc.

Provide FCF Margin
for Tarsus Pharmaceuticals Inc.

Show all solvency ratios
for Tarsus Pharmaceuticals Inc.

Provide D/E Ratio
for Tarsus Pharmaceuticals Inc.

Provide D/A Ratio
for Tarsus Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Tarsus Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Tarsus Pharmaceuticals Inc.

Provide Quick Ratio
for Tarsus Pharmaceuticals Inc.

Provide Current Ratio
for Tarsus Pharmaceuticals Inc.

Provide Cash Ratio
for Tarsus Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Tarsus Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Tarsus Pharmaceuticals Inc?

What is the current Free Cash Flow
of Tarsus Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Tarsus Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Tarsus Pharmaceuticals Inc

Current Assets 357.1m
Cash & Short-Term Investments 317m
Receivables 30.3m
Other Current Assets 9.9m
Non-Current Assets 19.2m
Long-Term Investments 3m
PP&E 4.2m
Intangibles 8.6m
Other Non-Current Assets 3.4m
Current Liabilities 65.9m
Accounts Payable 26.8m
Accrued Liabilities 39.1m
Non-Current Liabilities 72.9m
Long-Term Debt 71.7m
Other Non-Current Liabilities 1.2m
Efficiency

Earnings Waterfall
Tarsus Pharmaceuticals Inc

Revenue
129.6m USD
Cost of Revenue
-9.1m USD
Gross Profit
120.5m USD
Operating Expenses
-261.1m USD
Operating Income
-140.6m USD
Other Expenses
6.3m USD
Net Income
-134.3m USD

Free Cash Flow Analysis
Tarsus Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TARS Profitability Score
Profitability Due Diligence

Tarsus Pharmaceuticals Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
28/100
Profitability
Score

Tarsus Pharmaceuticals Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

TARS Solvency Score
Solvency Due Diligence

Tarsus Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
63/100
Solvency
Score

Tarsus Pharmaceuticals Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TARS Price Targets Summary
Tarsus Pharmaceuticals Inc

Wall Street analysts forecast TARS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TARS is 66.3 USD with a low forecast of 41.41 USD and a high forecast of 88.2 USD.

Lowest
Price Target
41.41 USD
14% Downside
Average
Price Target
66.3 USD
37% Upside
Highest
Price Target
88.2 USD
83% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TARS?

Click here to dive deeper.

Dividends

Tarsus Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TARS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TARS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Tarsus Pharmaceuticals Inc Logo
Tarsus Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1.8B USD

Dividend Yield

0%

Description

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 46 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The firm is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Contact

CALIFORNIA
Irvine
15440 Laguna Canyon Road
+19494099820.0
www.tarsusrx.com

IPO

2020-10-16

Employees

46

Officers

Co-Founder, President, CEO & Chairman
Dr. Bobak R. Azamian M.D.
CFO & Chief Strategy Officer
Mr. Jeffrey S. Farrow
Chief Operating Officer
Dr. Seshadri Neervannan Ph.D.
Chief Medical Advisor & Director
Dr. Elizabeth Yeu Lin M.D.
Head of Investor Relations
Mr. David Nakasone
General Counsel & Corporate Secretary
Dr. Bryan Wahl J.D., M.D.
Show More
Senior Director of Corporate Communications
Ms. Adrienne Kemp
Vice President of Marketing
Mr. Matthew Rossen M.B.A.
Vice President of Sales
Mr. Scott Youmans
Chief Human Resources Officer
Ms. Dianne C. Whitfield M.S.W.
Show Less

See Also

Discover More
What is the Intrinsic Value of one TARS stock?

The intrinsic value of one TARS stock under the Base Case scenario is 33.67 USD.

Is TARS stock undervalued or overvalued?

Compared to the current market price of 48.24 USD, Tarsus Pharmaceuticals Inc is Overvalued by 30%.

Back to Top